⚙️
🌟 Najlepsze dopasowanie
Wpisz szukaną frazę, aby zobaczyć propozycje AI.

The COVID-19 vaccine and the troublesome issue of storage

The COVID-19 vaccine and the troublesome issue of storage

Pharmaceutical companies Pfizer and BioNTech have developed a vaccine that is characterized by a surprisingly high, 95 percent effectiveness. The challenge is logistics, including storage in special medical freezers. A Polish manufacturer is rising to the challenge!

This good news for the whole world could be thwarted by just one small technical element. For the vaccine to maintain its properties and effectiveness, it must be transported and stored at a temperature of -80 degrees Celsius. That is quite a lot, considering the entire logistical undertaking behind transporting such material all over the world!

The American company’s vaccine, a hope for the fight against COVID-19

Information about the creation of an effective vaccine to fight COVID-19 seems to be confirmed, because just a few hours after the global news was announced, Polish Prime Minister Mateusz Morawiecki officially informed the media that he is willing to sign an agreement with the brand, under which the vaccines would reach the country. As a result of this agreement, up to 20 million vaccines would be transported to the country, which would be available to patients as early as the spring of 2021. There are many advantages to such a solution, and only one issue remains to be considered. Namely, COVID vaccines must be stored at the aforementioned temperature of minus 80 degrees Celsius. How do we plan to deal with this? Ideas have already emerged.

The vaccine from Pfizer and BioNTech is administered in two doses, three weeks apart, and immunity to the disease is said to appear 28 days after the first dose is administered, and one week after the second dose. By the end of this year, 50 million doses are to be ready, which will be enough to vaccinate 25 million people, and by the end of 2021, the company will be able to produce 1.3 billion doses. The first supply agreements for the vaccine have already been signed by countries such as: the USA, the EU, Great Britain, Canada, and Japan. Other major companies are also having success in vaccine production, such as Moderna or the British-Swedish company AstraZeneca in cooperation with the University of Oxford, and the American company Johnson & Johnson. It will therefore be a matter of time before more products are introduced to the pharmaceutical market.

What is the problem with storing the COVID-19 vaccine?

The problem of maintaining such a low temperature for an innovative vaccine is completely new and a significant challenge, because previous products did not require maintaining such a radical environment. Usually, vaccines required maintaining a temperature of 2-8 degrees, and at most down to -25 degrees Celsius. The difference in current requirements is therefore huge. -80 degrees is a level that only laboratory refrigerators can provide. If the transport company does not ensure such restrictive conditions, the entire vaccine purchase procedure will, simply put, go to waste. Pfizer COVID-19 vaccines transported in other conditions will not fulfill their intended role. On the contrary, the genetic material will disintegrate. Theoretically, buying a laboratory refrigerator is not a problem, but let’s remember that the purchase is to concern several million products. And that complicates things a bit.

The courier company UPS has already taken on the logistical solution of distributing vaccines around the world, and is reportedly creating a production line for special refrigerators in the United States. Other companies are also not idle in this regard. Unfortunately, the dangers we may encounter during the transport of the vaccine are multiplying, because it is not only about land transport, but also the aviation sector. On board transport planes, dry ice, which is produced from carbon dioxide, a byproduct of ethanol, will be necessary to maintain the appropriate conditions. And it is precisely its production that has unfortunately decreased significantly in recent times.

Pfizer, seeing these significant threats, is already creating special containers for 5,000 doses each, in which, using dry ice, a temperature of -75 degrees Celsius can be maintained for 10 days. This solution will facilitate transport. After thawing, the vaccine can be stored for one day in a refrigerator at 2-8 degrees C or for up to 2 hours at room temperature. After this time, however, it must reach the patient. Will we be able to handle such complex logistics of transporting this vaccine in Poland? After all, they will have to be transported around the country, and then stored in warehouses, pharmacies, and doctor’s offices.

The Polish manufacturer of refrigeration equipment, BOLARUS S.A. from Bochnia, which also specializes in the production of refrigeration and freezing equipment for hospitals, medical facilities, laboratories, and pharmacies, also has medical cabinets/freezers in its portfolio suitable for storing the COVID-19 vaccine from Pfizer and BioNTech. The manufactured refrigeration equipment meets the requirements of the Act of May 20, 2010, on medical devices and Directive 93/42/EEC. The quality and safety of the products is confirmed by the ISO 13485 quality certificate for medical devices and the CE0197 mark. The compliance procedure was carried out with the participation of the German notified body TUV Rheinland LGA Products GmbH. The manufactured devices are being submitted for registration with the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products. More about their products can be found here: https://www.bolarus.com.pl/pl/medycyna.html
If our domestic manufacturer prioritizes the production of refrigerators, there is a good chance for a positive resolution of the situation, and Poland will be completely independent in terms of vaccine distribution across the country!